Report
Anaïs Dudout
EUR 1017.86 Purchase single report

Etude de l'AG du 04/12/2017

Dans un contexte d'activité important, la société a convoqué une assemblée générale pour obtenir des liquidités via des opérations d'augmentation de capital avec et sans droit préférentiel de souscription. Elle avance en effet que les délégations votées lors de la précédente assemblée générale ne sont pas suffisantes pour réaliser une opération adaptée aux besoins de la société.

Si la société développe dans le rapport du conseil d'administration son activité lors de l'exercice, elle ne donne toutefois pas de projet spécifique pour justifier les opérations suivantes, portant sur des montants importants.
En raison des problèmes de montants demandés (sur plus de 100% du capital social), susceptibles de changer significativement le profil de la société ; et de la possibilité d'utilisation de ces opérations en période d'offre publique, Proxinvest recommandera l'opposition à la plupart de ces opérations (résolutions 1 à 11).

Underlying
Genomic Vision SA

Genomic Vision Sa. Genomic Vision SA is a France-based biotechnology company. It develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The Company uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. It develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Anaïs Dudout

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch